López-Catzín JF, Bolado-García PB, Gamboa-López GJ, Medina-Escobedo CE, Cambranes-Catzim LR

Language: Spanish
References: 18
Page: 576-580
PDF size: 268.28 Kb.

ABSTRACT

Background: Treating anemia of prematurity is transfused red blood cells and the use of erythropoiesis-stimulating agents. The aim of this article is to determine the correlation between the number of blood transfusions and the use of recombinant human erythropoietin in preterm infants with anemia.
Methods: A correlation study was performed in 80 cases of patients with anemia treated with transfusions and erythropoietin, were randomized into two groups: one was treated with transfusions (T) and one with transfusions and erythropoietin (E). Demographic variables, hemoglobin and hematocrit at the beginning and end of treatment and number of transfusions received were measured. The correlation was obtained through Spearman Rho, considering p ‹ 0.05 as statistically significant.
Results: The total number of units transfused in each group was lower in group E, which received two units less than the T group (p ‹ 0.05). The average CE transfused in group E was 4 ± 1.2 and 7 ± 1.2 for the group T. For the group E the correlation between gestational age and number of transfusions was moderately negative (-0348); birth weight and the number of packed red blood cells transfused were slightly negative (-0239). T group for the negative correlation between the same variables moderate slight negative (-0300) and (-0109), respectively.
Conclusions: Erythropoietin reduces the number of blood transfusions in preterm infants with anemia. Its use does not preclude the transfusion, the patient remains exposed to the risk of communicable diseases in this way.

REFERENCES

1. Plaisant F. Evolution of neonatal transfusion practices: current recommendations. Transfus Clin Biol. 2011;18:262-8.

2. Halpérin DS, Use of recombinant erythropoietin in treatment of the anemia of prematurity. Am J Pediatr Hematol Oncol. 1991;13(3):351-63.

3. Phibbs RH. Potential for treatment of anemia of prematurity with recombinant human erythropoietin. Curr Opin Pediatr. 1995; 7(2):140-5.

4. Strauss RG. Recobinant erythropoietin for the anemia of prematurity still a promise, not a panacea. J, Pediatr. 1997;131(5):653-5.

5. Figueras-Aloy J, Carbonell-Estrany X. Extracciones sanguíneas, política transfusional y eritropoyetina en el prematuro. An Esp Pediatr 1998;49:46-8.

6. Bishara N, Ohls RK. Current controversies in the management of the anemia of prematurity. Semin Perinatol. 2009;33(1):29-34.

7. Sola A. ¿Qué sabemos en la actualidad de EPO para la anemia de la prematurez? En: Diálogos en Neonatología: aprendiendo de las preguntas. Buenos Aires, Argentina: Edimed; 2009.

8. Sijó A, Saurez-Martinez G, Velázquez-Noda D, Méndez- Alarcon L, Alfonso-Dávila A, Vargas-Batista A, et al. Eficacia y seguridad de la Eritropoyetina en la anemia de la prematuridad. Rev Cubana Pediatr. 2013;85(2):202-12.

9. Manchón GJ, Natal-Pujol A, Coroleu LW, Zuasnábar CA, Badía-Barnusell J, Juncá-Piera J, et al. Estudio Multicentrico aleatorizado de administración de eritropoyetina en la anemia de la prematuridad. An Esp Pediatr. 1997; 46:587-92.

10. Niedderhauser C, Candotti D, Weingand T, Maier A, Tinguely C, Stolz M, et al. Reverse vertical transmission of hepatitis B virus (HBV) infection from a transfusion infected newbord to her mother. J Hepatol. 2012; 56:734-7.

11. Alarcón-Allen A, Baquero-Artigao F. Review and guidelines on the prevention diagnosis and treatment of post-natal cytomegalovirus infection. An Pediatr (Barc). 2011; 74(1): 52.e1-52.e13.

12. Reiter PD, Rosenberg AA, Valuck R, Novak K. Effect of short-term erythropoietin therapy in anemic premature infants. J Perinatol. 2005; 25(2):125-9.

13. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/ or low birth weight infants. Cochrane Database of Systematic Reviews 2012;9.

14. Figueras-Aloy F. Erythropoietin in neonates. An Pediatr (Barc). 2010;73(6):301-4.

15. Guzman-Cabañas JM, De la Torre-Aguilar MJ, Tofé- Valera IM, Muñoz-Gomariz E, Ordoñez-Díaz MD, Párraga-Quiles MJ, et al. Factores de riesgo implicados en la necesidad de tranfusion sanguínea en recién nacidos de muy bajo peso tratados con Eritropoyetina. An Pediatr (Barc). 2010;73(6):340-6.

16. Sastre-Huerta E, Alonso-Álvarez B, Montero-Alonso R, Álvarez-Martín T, Barbadillo-Izquierdo F, Carpintero- Martín I, et al .Eritropoyetina en la anemia de la prematuridad, Factores neonatales predictores de transfusiones. An Esp Pediatr 1998;49:49-54.

17. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. N Engl J Med. 1994;330(17):1173-8.

18. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomised, placebo controlled trial. J Pediatr. 1995;126(3):421-6.